EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors

Ning Wei, Natalie Thielen, Mahshid Mohammadi, Muzaffer Ahmed Bhat, Terence Li, Yan Sun, Seiya Kitamura, Edward Chu, Chaoyuan Kuang

Acta Pharmaceutica Sinica B · 2026-08 · 16 (8) · 5131-5147

DOI: 10.1016/j.apsb.2026.05.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-08. Verfasst von Ning Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, University of Texas MD Anderson Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BRAFCDK9Colorectal cancerDrug combinationDrug resistance

Autor:innen und Institutionen

  • Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • University of Texas MD Anderson Cancer Center
  • National Institutes of Health
  • NCI

Zitieren

APA

Wei, N., Thielen, N., Mohammadi, M., Bhat, M. A., Li, T., Sun, Y., Kitamura, S., Chu, E., & Kuang, C. (2026). CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors. Acta Pharmaceutica Sinica B, 16(8), 5131-5147. https://doi.org/10.1016/j.apsb.2026.05.008

Vancouver

Wei N, Thielen N, Mohammadi M, Bhat MA, Li T, Sun Y, et al. CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors. Acta Pharmaceutica Sinica B. 2026;16(8):5131-5147. doi:10.1016/j.apsb.2026.05.008

BibTeX
@article{Wei2026,
  author = {Wei, Ning and Thielen, Natalie and Mohammadi, Mahshid and Bhat, Muzaffer Ahmed and Li, Terence and Sun, Yan and Kitamura, Seiya and Chu, Edward and Kuang, Chaoyuan},
  title = {CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {5131--5147},
  doi = {10.1016/j.apsb.2026.05.008}
}
Kostenlos starten →